Delayed recovery of destocked molecules
Two large commercial molecules under destocking may not return as expected; management declined to quantify value, creating uncertainty.
high · analyst_questionCohance Lifesciences Ltd — Q4 FY26
Cohance Lifesciences reported FY26 revenue of ₹22.68B, down 13% YoY, with adjusted EBITDA margin of 21% (standalone 24.6%).
bearish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Middle East logistics cost inflation
Geopolitical tensions have increased freight and raw material costs, expected to impact gross margins by 100-150 bps in Q1 FY27.
medium · management_commentaryNJ Bio profitability timeline extended
NJ Bio's US facility expansion and bio conjugation capabilities will take >2 years to reach breakeven, delaying consolidated margin recovery.
medium · management_commentaryCustomer concentration in CDMO
Historical reliance on a few molecules led to revenue volatility; diversification is improving but still a risk.
high · data_observation